Plain-English translation of NCT06206564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether can help treat a condition called anal HSIL—abnormal, precancerous tissue in the anal area caused by HPV (human papillomavirus) infection. About two-thirds of participants will receive the active medication while the rest receive a placebo (inactive ointment), so researchers can see whether the treatment actually works. The study will track participants for several months to see if the medication can reduce or eliminate these abnormal cells.
High-grade anal tissue changes can eventually progress to cancer if left untreated, but current treatment options like surgery are invasive and uncomfortable. This trial is exploring whether this medication could offer a non-surgical alternative to prevent these abnormal cells from becoming cancerous.
You likely qualify if…
You likely don't qualify if…
You would apply the ointment (either the active medication or placebo) to the affected area for 5 days, with treatment cycles repeated at weeks 0, 2, 4, and 6. You would return for close follow-up visits with special imaging (called anoscopy) at weeks 8, 18, 30, and 42 so doctors can check whether the treatment is working. The entire study lasts about 10 months, and if the treatment is not working by week 18, you would receive standard surgical treatment instead.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States